Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
This research study is comparing different drug combinations as a possible treatment for
metastatic renal cell carcinoma (mRCC) and bone metastases.
The names of the study interventions involved in this study are:
- Combination of Radium-223 and Sorafenib
- Combination of Radium-223 and Pazopanib
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Bayer
Treatments:
Endothelial Growth Factors Mitogens Radium Ra 223 dichloride Sorafenib